JP2011503099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503099A5 JP2011503099A5 JP2010533285A JP2010533285A JP2011503099A5 JP 2011503099 A5 JP2011503099 A5 JP 2011503099A5 JP 2010533285 A JP2010533285 A JP 2010533285A JP 2010533285 A JP2010533285 A JP 2010533285A JP 2011503099 A5 JP2011503099 A5 JP 2011503099A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- alkyl
- oxo
- carboxamide
- tetrahydroindolizine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000003857 carboxamides Chemical class 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- MDINGYBMHOPYQH-UHFFFAOYSA-N 6-chloro-7-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(Cl)=C1NC1=CC=C(I)C=C1F MDINGYBMHOPYQH-UHFFFAOYSA-N 0.000 claims 1
- MIBKUYFVZVEADN-UHFFFAOYSA-N 6-fluoro-7-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(F)=C1NC1=CC=C(I)C=C1F MIBKUYFVZVEADN-UHFFFAOYSA-N 0.000 claims 1
- RBYIURLPUPZLAC-UHFFFAOYSA-N 6-fluoro-7-(2-fluoro-4-iodoanilino)-n-(3-hydroxypropoxy)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCCONC(=O)C1=C2CCCN2C(=O)C(F)=C1NC1=CC=C(I)C=C1F RBYIURLPUPZLAC-UHFFFAOYSA-N 0.000 claims 1
- UPLHQDFQQZDQQB-UHFFFAOYSA-N 7-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C=C1NC1=CC=C(I)C=C1F UPLHQDFQQZDQQB-UHFFFAOYSA-N 0.000 claims 1
- VSZNNXCPOIBREY-UHFFFAOYSA-N 7-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(C)=C1NC1=CC=C(I)C=C1F VSZNNXCPOIBREY-UHFFFAOYSA-N 0.000 claims 1
- BKZHHWSGUZPVIY-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-6-fluoro-n-(2-hydroxyethoxy)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(F)=C1NC1=CC=C(Br)C=C1F BKZHHWSGUZPVIY-UHFFFAOYSA-N 0.000 claims 1
- JNEXVTRXIDHXHP-UHFFFAOYSA-N 7-(4-bromo-2-fluoroanilino)-n-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(C)=C1NC1=CC=C(Br)C=C1F JNEXVTRXIDHXHP-UHFFFAOYSA-N 0.000 claims 1
- QUXCVJUXKUSVQD-UHFFFAOYSA-N 7-(4-ethynyl-2-fluoroanilino)-6-fluoro-n-(2-hydroxyethoxy)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(F)=C1NC1=CC=C(C#C)C=C1F QUXCVJUXKUSVQD-UHFFFAOYSA-N 0.000 claims 1
- PFCILVQESKRVSI-UHFFFAOYSA-N 7-(4-ethynyl-2-fluoroanilino)-n-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OCCONC(=O)C1=C2CCCN2C(=O)C(C)=C1NC1=CC=C(C#C)C=C1F PFCILVQESKRVSI-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DLUDRGRCQCHJFO-LLVKDONJSA-N n-[(2r)-2,3-dihydroxypropoxy]-7-(2-fluoro-4-iodoanilino)-5-oxo-2,3-dihydro-1h-indolizine-8-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C1=C2CCCN2C(=O)C=C1NC1=CC=C(I)C=C1F DLUDRGRCQCHJFO-LLVKDONJSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98727907P | 2007-11-12 | 2007-11-12 | |
| US60/987,279 | 2007-11-12 | ||
| PCT/US2008/082846 WO2009064675A1 (en) | 2007-11-12 | 2008-11-07 | Mapk/erk kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503099A JP2011503099A (ja) | 2011-01-27 |
| JP2011503099A5 true JP2011503099A5 (https=) | 2011-12-08 |
| JP5453290B2 JP5453290B2 (ja) | 2014-03-26 |
Family
ID=40340592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533285A Active JP5453290B2 (ja) | 2007-11-12 | 2008-11-07 | Ｍａｐｋ／ｅｒｋキナーゼ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8022057B2 (https=) |
| EP (1) | EP2227469B9 (https=) |
| JP (1) | JP5453290B2 (https=) |
| AR (1) | AR069462A1 (https=) |
| CA (1) | CA2705452C (https=) |
| CL (1) | CL2008003366A1 (https=) |
| ES (1) | ES2456966T3 (https=) |
| PE (1) | PE20090998A1 (https=) |
| TW (1) | TW200934775A (https=) |
| WO (1) | WO2009064675A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| WO2008140553A2 (en) | 2006-10-23 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| TW201038267A (en) * | 2008-04-21 | 2010-11-01 | Novartis Ag | Heterocyclic compounds as MEK inhibitors |
| CN103002911B (zh) | 2008-09-26 | 2015-08-26 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| BRPI0925050A2 (pt) * | 2009-04-21 | 2015-08-04 | Novartis Ag | Compostos heterocíclicos como inibidores de mek |
| JP5466767B2 (ja) * | 2009-11-04 | 2014-04-09 | ノバルティス アーゲー | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 |
| WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
| CN101747300B (zh) * | 2009-12-22 | 2012-11-07 | 上海大学 | 基于紫杉醇和氮芥的协同前药及其制备方法 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CN102020651B (zh) * | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| AR087309A1 (es) * | 2011-07-27 | 2014-03-12 | Glaxo Group Ltd | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| JP2015502958A (ja) * | 2011-12-09 | 2015-01-29 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんの処置のための併用療法 |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| AR099630A1 (es) | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| US9216163B2 (en) | 2013-05-20 | 2015-12-22 | Kyorin Pharmaceutical Co., Ltd. | Method of inhibiting angiogenesis |
| WO2014204263A1 (en) | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| SG11201700074YA (en) | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2017058007A1 (en) | 2015-10-01 | 2017-04-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| WO2020036852A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| CN111662282B (zh) * | 2019-03-07 | 2021-07-06 | 湖南化工研究院有限公司 | 氮杂环并吡啶类化合物及其中间体 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0670044B2 (ja) * | 1987-11-20 | 1994-09-07 | キッセイ薬品工業株式会社 | ４ｈ―キノリジン―４―オン誘導体 |
| AU616916B2 (en) | 1987-11-20 | 1991-11-14 | Kissei Pharmaceutical Co. Ltd. | 4h-quinolizin-4-one compounds exhibiting therapeutic activities |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| CA2532067C (en) | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| AU2005252110B2 (en) | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| WO2006056427A1 (en) | 2004-11-24 | 2006-06-01 | Laboratoires Serono S.A. | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| JP2008521858A (ja) | 2004-12-01 | 2008-06-26 | ラボラトワール セローノ ソシエテ アノニム | 過増殖性疾患を処置するための［１，２，４］トリアゾロ［４，３−ａ］ピリジン誘導体 |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| WO2008140553A2 (en) | 2006-10-23 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| EP2089359A2 (en) | 2006-10-31 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| TW201038267A (en) * | 2008-04-21 | 2010-11-01 | Novartis Ag | Heterocyclic compounds as MEK inhibitors |
| BRPI0925050A2 (pt) | 2009-04-21 | 2015-08-04 | Novartis Ag | Compostos heterocíclicos como inibidores de mek |
-
2008
- 2008-11-07 WO PCT/US2008/082846 patent/WO2009064675A1/en not_active Ceased
- 2008-11-07 JP JP2010533285A patent/JP5453290B2/ja active Active
- 2008-11-07 EP EP08849376.2A patent/EP2227469B9/en active Active
- 2008-11-07 CA CA2705452A patent/CA2705452C/en not_active Expired - Fee Related
- 2008-11-07 ES ES08849376.2T patent/ES2456966T3/es active Active
- 2008-11-07 US US12/267,353 patent/US8022057B2/en active Active
- 2008-11-11 TW TW097143569A patent/TW200934775A/zh unknown
- 2008-11-12 PE PE2008001910A patent/PE20090998A1/es not_active Application Discontinuation
- 2008-11-12 CL CL2008003366A patent/CL2008003366A1/es unknown
- 2008-11-12 AR ARP080104939A patent/AR069462A1/es unknown